Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway

Journal of Infection

Volumn 67, Issue 3, 2013, Pages 206-214

  Barnes, Rosemary A ^a   Stocking, Kate ^a   Bowden, Sarah ^a   Poynton, Matthew H ^b   White, P Lewis ^c  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

Antigen detection; Diagnosis; Invasive fungal disease; PCR

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS FUMIGATUS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; GRAFT RECIPIENT; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTEGRATIVE MEDICINE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PATIENT COMPLIANCE; PICHIA GUILLIERMONDII; PREDICTIVE VALUE; PSEUDALLESCHERIASIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS;

ANTIGEN DETECTION; DIAGNOSIS; INVASIVE FUNGAL DISEASE; PCR;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; COHORT STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; ROC CURVE; STEM CELL TRANSPLANTATION;

EID: 84881022595     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.04.020     Document Type: Article

References (30)

1. Voneiff M., Roos N., Schulten R., Hesse M., Zuhlsdorf M., Vandeloo J. Pulmonary aspergillosis - early diagnosis improves survival. Respiration 1995, 62(6):341-347.
2. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44(3):373-379.
3. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4):348-359.
4. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44(4):531-540.
5. Maertens J., Marchetti O., Herbrecht R., Cornely O.A., Fluckiger U., Frere P., et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011, 46(5):709-718.
6. Agrawal S., Hope W., Sinko J., Kibbler C. Optimizing management of invasive mould diseases. J Antimicrob Chemother 2011, 66:i45-i53.
7. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34(1):7-14.
8. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12):1813-1821.
9. White P.L., Barton R., Guiver M., Linton C.J., Wilson S., Smith M., et al. A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. J Mol Diagn 2006, 8(3):376-384.
10. White P.L., Bretagne S., Klingspor L., Melchers W.J.G., McCulloch E., Schulz B., et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010, 48(4):1231-1240.
11. Deeks J.J. Systematic reviews in health care - systematic reviews of evaluations of diagnostic and screening. Br Med J 2001, 323(7305):157-162.
12. Leeflang M.M.G., Bossuyt P.M.M., Irwig L. Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J Clin Epidemiol 2009, 62(1):5-12.
13. Furness P., Zimmern R.W.C., Adams M. The evaluation of diagnostic laboratory tests and complex biomarkers 2008, PHG Foundation, Cambridge, UK. http://www.phgfoundation.org.
14. Barnes R.A., White P.L., Bygrave C., Evans N., Healy B., Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009, 62(1):64-69.
15. Denning D.W., Kibbler C.C., Barnes R.A. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003, 3(4):230-240.
16. White P.L., Archer A.E., Barnes R.A. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005, 43(5):2181-2187.
17. White P.L., Linton C.J., Perry M.D., Johnson E.M., Barnes R.A. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006, 42(4):479-486.
18. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
19. de Pauw B.E., Viscoli C. Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?. J Antimicrob Chemother 2011, 66:i55-i58.
20. Ashley E.D. Pharmacoeconomics of antifungal therapy: current considerations. Curr Opin Infect Dis 2011, 24:S30-S40.
21. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103(4):1527-1533.
22. Meije Y., Aguado J.M., Cuenca-Estrella M. Silent and prolonged Aspergillus DNAemia in oncohematological patients receiving antifungal prophylaxis: a new phenomenon with clinical implications. Bone Marrow Transplant 2011, 46(7):1016-1017.
23. Nucci M., Nouer S.A., Grazziutti M., Kumar N.S., Barlogie B., Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010, 51(11):1273-1280.
24. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. JClin Oncol 2001, 19(1):253-259.
25. Erasmus J.J., Gladish G.W., Broemeling L., Sabloff B.S., Truong M.T., Herbst R.S., et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 2003, 21(13):2574-2582.
26. Georgiadou S.P., Sipsas N.V., Marom E.M., Kontoyiannis D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011, 52(9):1144-1155.
27. Weisser M., Rausch C., Droll A., Simcock M., Sendi P., Steffen I., et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005, 41(8):1143-1149.
28. Becker M.J., de Marie S., Willemse D., Verbrugh H.A., Bakker-Woudenberg I. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000, 38(4):1434-1438.
29. Buchheidt D., Hummel M., Schleiermacher D., Spiess B., Schwerdtfeger R., Cornely O.A., et al. Prospective clinical evaluation of a LightCycler (TM)-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004, 125(2):196-202.
30. Mennink-Kersten M., Ruegebrink D., Wasei N., Melchers W.J.G., Verweij P.E. Invitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 2006, 44(5):1711-1718.